The drug, also known as cetuximab, is an antibody designed to block a protein called epidermal growth factor.

Erbitux currently dominates the market for EGFR drugs, which block a protein called epidermal growth factor involved in cancer cell growth.

Erbitux, which is also approved to treat head and neck cancer, blocks a protein called epidermal growth factor and is given by infusion.

Erbitux is an antibody designed to block a protein called epidermal growth factor, which is believed to play a role in cancer cell growth.

The vaccine works by targeting a receptor to a type of protein called epidermal growth factor that has a mutation only found in cancer cells.

Erbitux, an antibody designed to block a protein called epidermal growth factor, is already approved for treating colorectal as well as head and neck cancers.

Erbitux, like Amgen Inc.'s AMGN.O Vectibix, is a biologic drug designed to block a protein called epidermal growth factor that cancer cells need to grow.